Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Written By Charlotte Kirby
Charlotte Kirby
Previous

CyberSmart Partners with Vodafone Ireland to Enable Secure Connectivity for SMEs
Next

Thought Machine launches cards and payments processing platform